Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Eli Lilly's Roche gets FDA clearance

The U.S. Food and Drug Administration has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline. The test, Elecsys pTau217, can run on existing analyzers and is part of a broader push for simpler diagnostic tools.

By Tertius News AI Desk 3 outlets · 3 articles Version 2 Coverage Aug 24, 2026 Published 19h ago

FDA Clears Roche and Eli Lilly's Blood Test for Alzheimer's Detection

The U.S. Food and Drug Administration (FDA) has cleared a blood test developed by Roche and partner Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older who are experiencing cognitive decline.

The test, named Elecsys pTau217, is a biomarker blood test that can help doctors determine whether patients are likely or unlikely to have Alzheimer's-related brain changes, according to Roche's announcement on Monday.

This clearance follows European approval for the test in May, marking a significant step in expanding access to less invasive diagnostic options.

Broader Access and Availability

The test can be run on more than 4,500 Roche laboratory analyzers already installed across the United States, which the company said could help broaden access.

In a separate development, Labcorp and Quest Diagnostics have announced plans to offer the test through their laboratory networks, potentially expanding its availability across the country.

Roche has not disclosed the test's price.

Context and Comparison with Existing Methods

Current methods to detect amyloid, a protein linked to Alzheimer's disease, typically rely on positron emission tomography (PET) scans or cerebrospinal fluid testing. These approaches can be expensive, invasive, and less widely available.

The FDA clearance comes as drugmakers and diagnostic companies race to develop simpler tests for Alzheimer's disease, driven by growing demand for earlier diagnosis and treatment.

In 2025, Fujirebio's Lumipulse became the first blood test cleared by the FDA to aid in the assessment of Alzheimer's disease, setting a precedent for this new diagnostic category.

Clinical Limitations and Guidance

Roche emphasized that Elecsys pTau217 is not intended to be used as a standalone diagnostic test. Results should be interpreted alongside other clinical information, the company said.

How each outlet told it

CNN — World as of Aug 24, 2026, 10:15 PM UTC

Framing: Headline names both companies (Roche and Eli Lilly) and the product type plus the regulatory milestone; it emphasizes the specific test and FDA clearance, without mentioning the target population or the test's limitations. — Measured. The tone is descriptive, using neutral language such as 'has cleared' and 'said'.

Facts Included:

The FDA cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people age 55 and older with cognitive decline.
The test is named Elecsys pTau217 and is a biomarker blood test that can help identify patients likely or unlikely to have Alzheimer’s-related brain changes, as stated by Roche on Monday.
The FDA clearance follows European approval for the test in May.
The test can be run on more than 4,500 Roche laboratory analyzers already installed in the United States, which could broaden access.
Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, potentially expanding availability.
Roche did not disclose the test’s price.
Current methods to detect amyloid rely on PET scans or cerebrospinal fluid testing, which can be expensive, invasive, and less widely available.
The FDA clearance comes as drugmakers and diagnostic companies race to develop simpler tests for Alzheimer’s disease amid growing demand for earlier diagnosis and treatment.
Fujirebio’s Lumipulse became the first blood test cleared by the FDA to aid in the assessment of Alzheimer’s disease in 2025.
The test is not intended to be used as a standalone diagnostic and results should be interpreted alongside other clinical information, said Roche.

Read the source article →

Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC

Framing: Headline emphasizes the FDA clearance and both Eli Lilly and Roche, but does not mention the specific test name, patient age group, or the purpose. — Measured, factual, descriptive; tone is neutral, reporting the FDA decision and company statements without evaluative language.

Facts Included:

The FDA cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline.
The test is named Elecsys pTau217 and is a biomarker blood test that can help identify patients likely or unlikely to have Alzheimer’s-related brain changes, as stated by Roche on Monday.
The FDA clearance follows European approval for the test in May.
The test can be run on more than 4,500 Roche laboratory analyzers already installed across the United States, which the company said could help broaden access.
Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, potentially expanding availability.
Roche did not disclose the test’s price.
Current methods to detect amyloid rely on PET scans or cerebrospinal fluid testing, which can be expensive, invasive and less widely available.
The FDA clearance comes as drugmakers and diagnostic companies race to develop simpler tests for Alzheimer’s disease amid growing demand for earlier diagnosis and treatment.
Fujirebio’s Lumipulse became the first blood test cleared by the FDA to aid in the assessment of Alzheimer’s disease in 2025.
The test is not intended to be used as a standalone diagnostic test and results should be interpreted alongside other clinical information, as stated by Roche.

Read the source article →

CP24 as of Aug 24, 2026, 3:16 PM UTC

Framing: Headline emphasizes the FDA clearance and that the test belongs to Eli Lilly and Roche, but does not mention the specific test name, age group, or clinical purpose. — Measured overcharge, with descriptive and neutral tone; no evaluative language.

Facts Included:

The FDA cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline.
The test is named Elecsys pTau217 and is a biomarker blood test that can help identify patients likely or unlikely to have Alzheimer’s-related brain changes, as stated by Roche on Monday.
The FDA clearance follows European approval for the test in May.
The test can be run on more than 4,500 Roche laboratory analyzers already installed across the United States, which the company said could help broaden access.
Labcorp and Quest Diagnostics plan to offer their test through their laboratory networks, potentially expanding availability.
Roche did not disclose the test’s price.
Current methods to detect amyloid rely on PET scans or cerebrospinal fluid testing, which can be expensive, invasive and less widely available.
The FDA clearance comes as drugmakers and diagnostic companies race to develop simpler tests for Alzheimer’s disease amid growing demand for earlier diagnosis and treatment.
Fujirebir’s Lumipulse became the first blood test cleared by the FDA to aid in the assessment of Alzheimer’s disease in 2025.
The test is not intended to be used as a standalone diagnostic test and results should be interpreted with other clinical information, per Roche.

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimThe FDA cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimThe test is named Elecsys pTau217 and is a biomarker blood test that can help identify patients likely or unlikely to have Alzheimer’s-related brain changes, as stated by Roche on Monday.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimThe FDA clearance follows European approval for the test in May.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimThe test can be run on more than 4,500 Roche laboratory analyzers already installed in the United States, which could broaden access.	ConfidenceMedium	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimLabcorp and Quest Diagnostics plan to offer the test through their laboratory networks, potentially expanding availability.	ConfidenceMedium	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimRoche did not disclose the test’s price.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimCurrent methods to detect amyloid rely on PET scans or cerebrospinal fluid testing, which can be expensive, invasive, and less widely available.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimThe FDA clearance comes as drugmakers and diagnostic companies race to develop simpler tests for Alzheimer’s disease amid growing demand for earlier diagnosis and treatment.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimFujirebio’s Lumipulse became the first blood test cleared by the FDA to aid in the assessment of Alzheimer’s disease in 2025.	ConfidenceHigh	StatusMulti-source (2 outlets) via Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC
ClaimThe test is not intended to be used as a standalone diagnostic and results should be interpreted alongside other clinical information, said Roche.	ConfidenceHigh	StatusMulti-source (3 outlets) via CNN — World as of Aug 24, 2026, 10:15 PM UTC, Bnn Bloomberg as of Aug 24, 2026, 3:16 PM UTC, CP24 as of Aug 24, 2026, 3:16 PM UTC

Transparency & Audit Trail

3 outlets · 3 articles consulted: CNN — World, Bnn Bloomberg, CP24 10 claims extracted Version 2 Written 2026-08-24